AI Generated
Jun 28, 2026, 09:55
Utkarsh Pandey: Japan Approves Wayrilz for ITP Patients
Utkarsh Pandey, Principal Study Data Manager Leader at Sanofi, shared a post on LinkedIn:
“Exciting news!
Wayrilz (rilzabrutinib) has received approval in Japan for the treatment of immune thrombocytopenia (ITP).
This approval is supported by the LUNA 3 phase 3 study, which demonstrated rapid and durable platelet response. It is a significant milestone for patients managing this rare, complex immune disease.”
Stay updated with Hemostasis Today.
-
Jun 28, 2026, 10:34Heghine Khachatryan: Menarche as the First ‘Bleeding Challenge’
-
Jun 28, 2026, 10:13Mohammed Alharbi: Assessing Warfarin Management and Anticoagulation Quality in Older Populations
-
Jun 28, 2026, 10:03Rick Kapur: Current Understanding of FNAIT Regarding Diagnostics, Pathophysiology and Management
-
Jun 28, 2026, 09:41Sung-mok Jung: How Environmental Drivers Influence SFTS Occurrence
-
Jun 28, 2026, 05:17Burcu Tunakan: Turning Collaboration into Better Outcomes for People with Hemophilia
-
Jun 28, 2026, 05:08Kathrine Kaspersen: The Power of Voluntary Plasma Donation
-
Jun 28, 2026, 04:55Sana Helani: Challenging Common Assumptions in Anemia Management
-
Jun 28, 2026, 04:55Samwel Mikaye: The Collapse of Coagulation Control in Disseminated Intravascular Coagulation
-
Jun 28, 2026, 04:45Abolfazl Miri: Improving ITP Diagnosis with Readily Available Hematological Indices